XML 47 R36.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Jan. 31, 2010 contingent_value_right | Sep. 30, 2022 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2021 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Number of CVR Series | contingent_value_right | 4 |  |  |
Transferred over Time | Phase 3 Clinical Trial |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Gross contract asset |  | $ 10,000,000 | $ 10,000,000 |
Maximum | Transferred over Time | Development, Regulatory, & Commercial Milestones and Tiered Royalties |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Investments |  | 375,000,000 | 375,000,000 |
Metabasis |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Number of CVRs issued per acquiree share | contingent_value_right | 4 |  |  |
Number of CVRs issued from each CVR series | contingent_value_right | 1 |  |  |
Frequency of cash payments to CVR holders | 6 months |  |  |
Mark-to-market adjustment of CVR liability |  | 100,000 | (900,000) |
Icagen |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Mark-to-market adjustment of CVR liability |  | (200,000) | (500,000) |
Payment for contingent consideration liabilities |  |  | 1,500,000 |
xCella |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Payment for contingent consideration liabilities |  | 1,000,000 | 1,000,000 |
xCella | Earnout Rights for Partner Research and Development |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Earnout rights recognized |  | 500,000 | 1,400,000 |
Recurring |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Total assets |  | 117,291,000 | 117,291,000 | $ 321,586,000
Amounts owed to former licensor |  | 73,000 | 73,000 | 86,000
Total liabilities |  | 8,701,000 | 8,701,000 | 11,157,000
Recurring | Short-term investments |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Investments, fair value |  | 99,026,000 | 99,026,000 | 290,697,000
Recurring | Common Stock |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Investments, fair value |  | 18,265,000 | 18,265,000 | 30,889,000
Recurring | Contingent Liabilities | CyDex |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 308,000 | 308,000 | 349,000
Recurring | Contingent Liabilities | Metabasis |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 2,507,000 | 2,507,000 | 3,358,000
Recurring | Contingent Liabilities | Icagen |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 5,333,000 | 5,333,000 | 7,364,000
Recurring | Contingent Liabilities | xCella |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 480,000 | 480,000 | 0
Recurring | Level 1 |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Total assets |  | 22,914,000 | 22,914,000 | 40,624,000
Amounts owed to former licensor |  | 73,000 | 73,000 | 86,000
Total liabilities |  | 73,000 | 73,000 | 86,000
Recurring | Level 1 | Short-term investments |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Investments, fair value |  | 4,649,000 | 4,649,000 | 9,735,000
Recurring | Level 1 | Common Stock |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Investments, fair value |  |  |  | 30,889,000
Recurring | Level 1 | Contingent Liabilities | CyDex |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 0 | 0 | 0
Recurring | Level 1 | Contingent Liabilities | Metabasis |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 0 | 0 | 0
Recurring | Level 1 | Contingent Liabilities | Icagen |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 0 | 0 | 0
Recurring | Level 1 | Contingent Liabilities | xCella |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 0 | 0 | 0
Recurring | Level 2 |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Total assets |  | 94,145,000 | 94,145,000 | 280,553,000
Amounts owed to former licensor |  | 0 | 0 | 0
Total liabilities |  | 2,507,000 | 2,507,000 | 3,358,000
Recurring | Level 2 | Short-term investments |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Investments, fair value |  | 94,145,000 | 94,145,000 | 280,553,000
Recurring | Level 2 | Common Stock |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Investments, fair value |  | 0 | 0 | 0
Recurring | Level 2 | Contingent Liabilities | CyDex |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 0 | 0 | 0
Recurring | Level 2 | Contingent Liabilities | Metabasis |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 2,507,000 | 2,507,000 | 3,358,000
Recurring | Level 2 | Contingent Liabilities | Icagen |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 0 | 0 | 0
Recurring | Level 2 | Contingent Liabilities | xCella |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 0 | 0 | 0
Recurring | Level 3 |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Total assets |  | 232,000 | 232,000 | 409,000
Amounts owed to former licensor |  | 0 | 0 | 0
Total liabilities |  | 6,121,000 | 6,121,000 | 7,713,000
Recurring | Level 3 | Short-term investments |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Investments, fair value |  | 232,000 | 232,000 | 409,000
Recurring | Level 3 | Common Stock |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Investments, fair value |  | 0 | 0 | 0
Recurring | Level 3 | Contingent Liabilities | CyDex |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 308,000 | 308,000 | 349,000
Recurring | Level 3 | Contingent Liabilities | Metabasis |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 0 | 0 | 0
Recurring | Level 3 | Contingent Liabilities | Icagen |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | 5,333,000 | 5,333,000 | 7,364,000
Recurring | Level 3 | Contingent Liabilities | xCella |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |
Contingent liabilities |  | $ 480,000 | $ 480,000 | $ 0

X
- Definition Amounts Owed To Former Licensor, Fair Value Disclosure + References No definition available. + Details
Name: | lgnd_AmountsOwedToFormerLicensorFairValueDisclosure
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Contingent Consideration, Gain (Loss) Recognized on Contingency + References No definition available. + Details
Name: | lgnd_BusinessCombinationContingentConsiderationGainLossRecognizedOnContingency
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Contingent Consideration, Liability, Fair Value Disclosure + References No definition available. + Details
Name: | lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders + References No definition available. + Details
Name: | lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series + References No definition available. + Details
Name: | lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Number of Contingent Value Rights Issued per Acquiree Share + References No definition available. + Details
Name: | lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Contingent Value Rights Series + References No definition available. + Details
Name: | lgnd_NumberOfContingentValueRightsSeries
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 7A -URI https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 50 -Paragraph 14 -URI https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.1(h)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910 + Details
Name: | us-gaap_Investments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties. + References No definition available. + Details
Name: | us-gaap_LiabilitiesFairValueAdjustment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 17 -Subparagraph (ee) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lgnd_IcagenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lgnd_XCellaBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=lgnd_EarnoutRightsForPartnerResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=lgnd_ContingentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lgnd_CyDexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |